مباشر
FierceBiotechIn another reversal for rare disease field, FDA to reconsider Regenxbio gene therapyEndpoints NewsMerck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 winFierceBiotechMerck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitisPharmaVoicePfizer CFO departs for consumer goods sectorFierceBiotechSanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic diseasePharmaVoiceBacked by Sanofi and Roche, Orano Med chases radiopharma leadershipBioWorldBrightgene Bio-Medical Technology synthesizes new GIPR, GCGR and GLP-1R agonistsBioWorldTennor Therapeutics discovers new antibacterial agentsBioWorldAsahi Kasei Therapeutics reports new TNFR1 antagonistsBioWorldNLRP3 inflammasome inhibitors disclosed in Evotec patentBioWorldF2G preps NDA for first new antifungal in 20 years on solid phase IIILabiotech8 of the most expensive drugs in biopharma: Unraveling the costliest medications

الأرشيف

الأحدث الأقدم
الإجمالي 13655
صفحة 164 / 759
بحث --